What ChondroFiller injection involves for the hip

For patients wondering whether this treatment means an operation, the short answer is no. ChondroFiller injection for the hip is delivered as an outpatient appointment under local anaesthesia — no general anaesthetic, no surgical incision, and no theatre admission.

The material itself is a CE-marked Class III injectable collagen scaffold manufactured by Meidrix Biomedicals GmbH in Germany. It arrives as a liquid and, once placed precisely into the cartilage defect, self-gels within approximately 3–5 minutes to form a stable, three-dimensional framework inside the lesion.

The appointment typically covers a consultation and imaging review, the injection itself, intravenous antibiotics, and a six-week follow-up — all included within a single package. The scaffold is imported into the UK under individual patient prescription and accessed through private specialists; it is not NHS-commissioned and is not covered by major UK insurers such as Bupa or AXA. Guide costs across UK centres range from approximately £3,000 to £8,000, though patients should confirm exact pricing directly with the treating specialist, as packages vary.

Because the treatment is self-funded and falls outside standard insurance pathways, understanding what is included in any quoted fee — and what follow-up looks like beyond six weeks — is a practical question worth raising at the initial assessment.

How the scaffold works — and why placement precision matters

The collagen scaffold works by acting as a chemotactic matrix — a structure that draws the body's own repair cells towards the lesion site. Once placed inside the defect pocket, it creates a three-dimensional framework that recruits progenitor cells from the adjacent synovium and subchondral bone. Those cells colonise the scaffold, supporting the body's own repair processes rather than replacing cartilage directly. This process is called acellular matrix-induced chondrogenesis (ACIC): acellular because no donor cells are introduced, and matrix-induced because the scaffold itself triggers the biological response. As host-derived tissue establishes itself, the collagen gradually biodegrades.

The biology depends entirely on the scaffold physically occupying the discrete defect. Gel that disperses into the surrounding joint space cannot form a structured template — the repair response does not occur away from the lesion pocket itself.

This is why real-time ultrasound guidance is a mechanistic requirement rather than an optional safety measure. Published orthobiologics research cited in the clinical literature estimates that up to 30% of intra-articular injections performed without imaging guidance fail to achieve intralesional placement. In a procedure where precise positioning is the difference between a functional scaffold and material that disperses without effect, image-guided delivery is not a refinement — it is what makes the treatment work.

Which hip patients are typically assessed as candidates

Candidacy for ChondroFiller hip injection rests on several overlapping filters — and understanding them helps frame the conversation with a specialist before any assessment appointment.

The strongest candidates

The joint profile that tends to produce the best outcomes combines two criteria: a Tönnis grade of 0 or 1, and an MRI- or arthroscopy-confirmed focal cartilage defect measuring roughly 1.5–6 cm². Tönnis grade reflects how much background arthritis is already present in the hip; grade 0 means none, grade 1 means very mild changes. Patients with Tönnis grade 2 or 3 — where pre-existing arthritic change is more advanced — have shown consistently poor results in published cohort data and are generally not considered suitable for the focal repair pathway.

Intact subchondral bone beneath the defect is a separate prerequisite. If the bone immediately underlying the cartilage loss is significantly compromised, the scaffold cannot integrate, and the treatment is unlikely to be effective.

Hip cartilage lines two opposing surfaces simultaneously — the curved acetabulum (socket) and the femoral head (ball) — and focal defects on either surface are in principle addressable. Where femoroacetabular impingement (FAI) is also present, correcting it at the same session appears to improve outcomes in the available cohort data, since untreated cam-type FAI can accelerate cartilage damage at the anterosuperior acetabulum.

Diffuse osteoarthritis: a separate pathway

For patients with more widespread Kellgren-Lawrence Grade III–IV osteoarthritis rather than a discrete focal lesion, a different injectable approach applies: the scaffold is used to coat the worn joint surface broadly rather than fill a single defect pocket. In this context the size thresholds relevant to surgical cartilage repair do not apply.

None of these criteria reliably translate into a self-assessment — even 'bone on bone' patients are not automatically excluded from evaluation. A consultant-led assessment, with imaging review, is needed to confirm whether the hip anatomy and biological environment are genuinely suitable.

The ultrasound-guided injection pathway in practice

Arriving prepared makes a practical difference. Bringing any prior hip MRI reports or arthroscopy findings — including disc and report, not just the images — allows the clinician to map the defect in detail before the appointment begins, rather than relying on recall or incomplete notes. That mapping informs how the needle will be positioned and confirms that the defect geometry is compatible with the injectable approach.

During the appointment itself, the clinician uses real-time ultrasound to visualise the defect pocket directly and confirm that the needle tip is seated within it before deploying the scaffold. This confirmation step is the practical expression of what the biology requires: the material must occupy the lesion, not the surrounding joint space. Local anaesthetic is applied to minimise discomfort at the injection site, and antibiotics are given intravenously during the session as standard infection prophylaxis.

The six-week follow-up serves a specific monitoring purpose rather than being a formality. The clinician is looking for early signals of scaffold integration and tracking the symptom trajectory — both of which can shift in the weeks after placement. Attending even when early discomfort has already settled is worthwhile: asymptomatic improvement at five weeks does not confirm that integration is proceeding as expected, and the follow-up review provides the clearest early read on how the hip is responding.

What the clinical evidence shows — and where gaps remain

Three published hip-specific studies currently underpin the evidence base. Perez-Carro et al. (2021, PMC8322278) described arthroscopic needle-and-curette delivery into acetabular defects, documenting the technical approach and early outcomes. Mazek et al. (2021, PMC8460160) reported a 26-patient cohort with isolated acetabular defects greater than 2 cm², confirmed FAI, and Tönnis grade 1 or below. A 2025 case series published in the Journal of Orthopaedic Case Reports extended the indication to isolated osteochondral defects of the femoral head — the ball surface rather than the socket.

Across these hip cohorts, reported symptom relief ranges from approximately 70–85%, with reoperation rates cited between 3–8%. These are observed figures from relatively small series, not benchmarks from controlled trials, and should be understood as early signals rather than settled probabilities.

Where the evidence is incomplete

No randomised controlled trial has directly compared ultrasound-guided injectable delivery with arthroscopic placement in the hip — the route used in all three published studies. Long-term follow-up data beyond three to five years are currently absent, so how outcomes hold over a decade remains unknown. Histologically, whether the repair tissue formed under injectable conditions is hyaline cartilage or the more resilient fibrocartilage has not been characterised in hip patients — a distinction that matters because fibrocartilage wears more readily under load.

For patients already reassured by the general numbers, that last question is the most clinically meaningful one to raise with a specialist: what tissue type is likely forming, and what does that imply for activity levels and longer-term joint health?

Finding a specialist and questions worth asking

Going into assessment with the right preparation — and the right questions — makes the difference between a productive first consultation and one spent gathering background that could have been brought along.

If hip MRI or arthroscopy reports exist, bring the full disc and written report rather than just the images. Clinicians experienced in image-guided scaffold placement use that documentation to confirm defect size and subchondral bone integrity before the appointment begins, rather than working from incomplete notes.

Questions worth raising at consultation

• What is my Tönnis grade, and what does that mean for my pathway options?
• Am I being assessed for focal defect repair or the diffuse osteoarthritis pathway?
• Is femoroacetabular impingement present, and would it be addressed at the same session?
• What does the full package cost cover, and which follow-up appointments are included?

Not every MSK injector offers ChondroFiller for the hip specifically — experience with hip cartilage assessment and image-guided scaffold injection matters when selecting a clinician. Search MSK is a UK-wide specialist directory where patients can filter by region and treatment offered to find a clinician with that particular expertise near them.

Because treatment is self-funded, asking the clinic to itemise the full package — scaffold, injection, intravenous antibiotics, and follow-up care — before booking avoids any uncertainty about what is and is not included.